Risk of cancer after biologic and targeted synthetic DMARDs initiation in patients with rheumatic diseases and a history of prior malignancy: data from the BIOBADASER registry
14/08/2023
J. Molina Collada1,2, F. Alonso3, C. Bohórquez4, C. Díaz Torné5, C. Pérez García6, J.M. Blanco Madrigal7 , P. Vela8 and I. Castrejón1,2
SER 2022
C020
https://static.elsevier.es/reuma/reumacongreso2022.pdf